[1]加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美.非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验[J].心血管病学进展,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
　Jiayina Jiaerken,TANG Baopeng,ZHOU Xianhui,et al.Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>[J].Advances in Cardiovascular Diseases,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
点击复制

非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年12期
页码:
1141
栏目:
论著
出版日期:
2022-12-25

文章信息/Info

Title:
Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>
作者:
加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美
(新疆医科大学第一附属医院心脏中心起搏电生理科,新疆 乌鲁木齐 830054)
Author(s):
Jiayina Jiaerken;  TANG Baopeng;  ZHOU Xianhui;  LI Yaodong;  LU Yanmei
(Department of Cardiology,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
关键词:
心房颤动; 经导管消融术; 左心耳封堵术; 卒中
Keywords:
Atrial fibrillation;  Catheter ablation;  Left atrial appendage closure;  Stroke
DOI:
10.16806/j.cnki.issn.1004-3934.2022.12.019
摘要:
目的 探讨非瓣膜性心房颤动（房颤）患者行消融联合左心耳封堵的“一站式”手术治疗的有效性和安全性。方法 单中心回顾性分析，纳入2019年2月—2021年4月在本院行“一站式”手术的非瓣膜性房颤患者（50例）为试验组，同期在本院行单纯房颤消融术的非瓣膜性房颤患者（50例）为对照组，比较两组围手术期、术后3个月、6个月进行随访的房颤复发率、卒中等并发症发生率以及心脏结构和功能的改善，评价“一站式”手术的短期有效性和安全性。结果 试验组房颤复发率（18%）低于对照组（34%），两组患者血液学指标较术前均有一定程度的改善，术后6个月数据中试验组E/A值≥1的患者占比高于对照组（P＜0.001）。两组患者均未发生脑卒中、空气栓塞和死亡，试验组心包积液发生率高于对照组，肺实质渗出发生率低于对照组，出血、血肿、胸腔积液和心脏压塞发生率与对照组类似。对照组围手术期发生2例下肢静脉血栓，术后3个月发生2例短暂性脑缺血发作、1例肺栓塞，术后6个月未发生血栓栓塞事件，试验组未出现血栓栓塞事件。结论 对于卒中或出血高危、不耐受长期抗凝治疗的非瓣膜性房颤患者，“一站式”手术可作为一种新的安全有效的治疗策略。
Abstract:
Aim To investigate the short-term effectiveness and safety of "one-step" surgical strategy of combining atrial fibrillation (Af) ablation with left atrial appendage occlusion (LAAO) in patients with non-valvular Af. Methods It’s a single-center retrospective analysis. A total of 50 patients underwent Af ablation and LAAO in our hospital from February 2019 to April 2021 were enrolled and classified into experimental group. Another 50 patients contemporarily underwent Af ablation alone were set as control group. To evaluate the short-term efficacy and safety of one-step surgery ,all patients were followed up at perioperation,3 and 6 months after operation by comparing the incidence of recurrent Af,stroke and other complications as well as improvements of cardiac structure and function. Results The recurrence rate of Af was lower in experimental group (18%) than control group (34%) ,and postoperatively hematological indexes of two groups got partly improved. From the data of 6 months after operation,the proportion of patients with E/A≥1 was higher in experimental group than control group (P＜0.001). There was no stroke,air embolism or death occurred. The incidence of pericardial effusion was higher in experimental group,the incidence of pulmonary parenchymal exudation was lower than control group,while the incidence of bleeding,hematoma,pleural effusion and cardiac tamponade were similar between two groups. In control group,2 cases of lower extremity venous thrombosis occurred during perioperation period,2 cases of transient ischemic attack and 1 case of pulmonary embolism occurred in 3 months after operation. No thromboembolic event occurred at 6 months after operation and in experimental group. Conclusion For patients with non-valvular Af at high risk of stroke or bleeding and not tolerating long-term anticoagulant therapy ,"one-step" surgery may serve as a new safe and effective treatment strategy

参考文献/References:

[1] Parameswaran R,Al-Kaisey AM,Kalman JM. Catheter ablation for atrial fibrillation:current indications and evolving technologies[J]. Nat Rev Cardiol,2021,18(3):210-225.

[2] January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation,2019,140(2):e125-e151.

[3] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,心房颤动防治专家工作委员会,等. 左心耳干预预防心房颤动患者血栓栓塞事件:目前的认识和建议(2019)[J]. 中华心律失常学杂志,2019(5):372-392.

[4] He B,Jiang LS,Hao ZY,et al. Combination of ablation and left atrial appendage closure as "One-stop" procedure in the treatment of atrial fibrillation:current status and future perspective[J]. Pacing Clin Electrophysiol,2021,44(7):1259-1266.

[5] 何斌,杜先锋,刘晶,等. 非瓣膜性心房颤动"一站式"介入治疗的安全性与有效性分析[J]. 中华心律失常学杂志,2017,21(3):197-202.

[6] Phillips KP,Pokushalov E,Romanov A,et al. Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation:multicentre registry results of feasibility and safety during implant and 30 days follow-up[J]. Europace,2018,20(6):949-955.

[7] Fauchier L,Philippart R,Clementy N,et al. How to define valvular atrial fibrillation?[J]. Arch Cardiovasc Dis,2015,108(10):530-539.

[8] de Gennaro L,Brunetti ND,Montrone D,et al. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation[J]. Eur J Clin Invest,2012,42(4):371-375.

[9] 王玲,吴瑛,吴芳琴,等. 脑钠肽和氨基末端B型钠尿肽前体与心脏术后心房颤动关系的荟萃分析[J]. 中华心律失常学杂志,2013(2):118-122.

[10] Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace,2016,18(11):1609-1678.

[11] Calkins H,Kuck KH,Cappato R,et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation:recommendations for patient selection,procedural techniques, patient management and follow-up,definitions,endpoints,and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA),a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC),American Heart Association (AHA),the Asia Pacific Heart Rhythm Society (APHRS),and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association,the European Cardiac Arrhythmia Society,the European Heart Rhythm Association,the Society of Thoracic Surgeons,the Asia Pacific Heart Rhythm Society,and the Heart Rhythm Society[J]. Heart Rhythm,2012,9(4):632-696.

[12] Hoit BD. Pericardial effusion and cardiac tamponade in the new millennium[J]. Curr Cardiol Rep,2017,19(7):57.

[13] 李亚会,黄从新. 左心耳封堵术常见并发症及其防治[J]. 心血管病学进展,2021,42(5):408-410.

[14] AlTurki A,Joza J,Bernier ML,et al. Catheter ablation of atrial fibrillation:current and evolving indications[J]. Can J Cardiol,2020,36(10):1685-1689.

[15] 宋卫锋,陈珂,马继芳,等. 导管射频消融在持续性心房颤动合并射血分数值降低的心力衰竭患者中的应用[J]. 中国心脏起搏与心电生理杂志,2021,35(1):33-36.

[16] Ganesan AN,Shipp NJ,Brooks AG,et al. Long-term outcomes of catheter ablation of atrial fibrillation:a systematic review and meta-analysis[J]. J Am Heart Assoc,2013,2(2):e4549.

[17] 白金龙,李洪仕,蔡衡. 非瓣膜性心房颤动患者导管消融术后抗凝策略的研究进展[J]. 心血管病学进展,2021,42(1):30-34+42.

[18] Wintgens L,Romanov A,Phillips K,et al. Combined atrial fibrillation ablation and left atrial appendage closure:long-term follow-up from a large multicentre registry[J]. Europace,2018,20(11):1783-1789.

[19] 唐恺,张敬莹,赵冬冬,等. 左心耳封堵联合导管消融治疗心房颤动的有效性和安全性[J]. 中华心律失常学杂志,2016,20(5):384-388.

[20] 阮中宝,任寅,陈各才,等. 非瓣膜性心房颤动12例“一站式”介入治疗临床分析[J]. 中西医结合心血管病电子杂志,2018,6(29):180-181.

[21] 胡志成,蒋超,刘尚雨,等. 中国心房颤动介入治疗现况与质量分析[J]. 中华心血管病杂志,2021,49(3):224-228.

[22] Verma A,Jiang CY,Betts TR,et al. Approaches to catheter ablation for persistent atrial fibrillation[J]. N Engl J Med,2015,372(19):1812-1822.

[23] Reddy VY,Neu?il P,Peichl P,et al. A lattice-tip temperature-controlled radiofrequency ablation catheter:durability of pulmonary vein isolation and linear lesion block[J]. JACC Clin Electrophysiol,2020,6(6):623-635.

[24] Oikonomou E,Zografos T,Papamikroulis GA,et al. Biomarkers in atrial fibrillation and heart failure[J]. Curr Med Chem,2019,26(5):873-887.

[25] 孙静美,尹德春,曲秀芬. 炎症信号与心房颤动[J]. 心血管病学进展,2020,41(1):31-34.

[26] 朱世杰,郑慕晗,颜如玉,等. 一站式手术对房颤消融成功率及心功能的影响:一项倾向评分匹配研究[J]. 南方医科大学学报,2020,40(10):1415-1421.

[27] 夏林莺,刘毅,陶凌. Watchman封堵器左心耳封堵术后器械相关血栓的发生率及临床转归的Meta分析[J]. 中国介入心脏病学杂志,2020,28(3):153-158.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(12):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(12):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(12):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(12):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(12):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2023-02-03